Which nephritis is sparsentan/sparsentan mainly used to treat?

Sparsentan is an innovative dual-action drug that mainly acts by antagonizing endothelin receptors and angiotensin II receptors and has potent anti-fibrotic and anti-inflammatory effects. It is currently being studied and developed for the treatment of some refractory and rapidly progressive kidney diseases, especially focal segmental glomerulosclerosis (FSGS) and primary immunoglobulin A nephropathy (IgAN).

Focal segmental glomerulosclerosis (FSGS) is a chronic kidney disease caused by glomerular damage and fibrosis. It usually presents with symptoms such as proteinuria, gradual decline in kidney function, and edema. The endothelin and angiotensin II systems in FSGS patients are often abnormally activated, leading to continued kidney damage and functional decline. By dually inhibiting endothelin and angiotensin II receptors, sparsentane can effectively reduce the activation of these pathophysiological pathways, thereby inhibiting the inflammatory response and fibrosis process in the kidney and improving patients' symptoms and renal function.

IgA nephropathy (IgAN) is another common chronic kidney disease, which is usually triggered by an abnormal response of the immune system, leading to the deposition of immune complexes in the kidneys, causing damage to the renal tubules and glomeruli. Patients with IgAN often develop proteinuria and hematuria, which may lead to renal failure as the disease progresses. Sparsentane is also being studied for its therapeutic potential in patients with IgAN because of its ability to reduce inflammation and fibrosis in the kidneys and reduce damage to the kidneys caused by the immune response.

Sparsentan's mechanism of action and clinical utility make it a promising therapeutic option for the treatment of these renal diseases associated with fibrosis, immune response, and abnormalities in the endothelin and angiotensinII system. While sparsentane's use in these conditions is still in clinical trials, preliminary results suggest it has significant efficacy, particularly in reducing proteinuria and protecting kidney function.

Reference materials:https://www.sparsentan.com/